Corbus Pharmaceuticals Holdings Inc
CRBP
View Detailed Chart
8.317USD
+0.147+1.80%
Market hours （ET）Quotes delayed by 15 min
104.25MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.80%
5 Days
-0.51%
1 Month
-12.27%
6 Months
+3.19%
Year to Date
+2.17%
1 Year
-32.87%
View Detailed Chart
TradingKey Stock Score of Corbus Pharmaceuticals Holdings Inc
Currency: USD Updated: 2026-01-15Key Insights
Corbus Pharmaceuticals Holdings Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.33.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Corbus Pharmaceuticals Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Corbus Pharmaceuticals Holdings Inc Highlights
StrengthsRisks
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Fairly Valued
The company’s latest PE is -1.49, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.91M shares, decreasing 29.87% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 612.03K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
42.333
Target Price
+433.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Corbus Pharmaceuticals Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Corbus Pharmaceuticals Holdings Inc Info
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Ticker SymbolCRBP
CompanyCorbus Pharmaceuticals Holdings Inc
CEOCohen (Yuval)
Websitehttps://www.corbuspharma.com/
FAQs
What is the current price of Corbus Pharmaceuticals Holdings Inc (CRBP)?
The current price of Corbus Pharmaceuticals Holdings Inc (CRBP) is 8.317.
What is the symbol of Corbus Pharmaceuticals Holdings Inc?
The ticker symbol of Corbus Pharmaceuticals Holdings Inc is CRBP.
What is the 52-week high of Corbus Pharmaceuticals Holdings Inc?
The 52-week high of Corbus Pharmaceuticals Holdings Inc is 20.560.
What is the 52-week low of Corbus Pharmaceuticals Holdings Inc?
The 52-week low of Corbus Pharmaceuticals Holdings Inc is 4.640.
What is the market capitalization of Corbus Pharmaceuticals Holdings Inc?
The market capitalization of Corbus Pharmaceuticals Holdings Inc is 104.25M.
What is the net income of Corbus Pharmaceuticals Holdings Inc?
The net income of Corbus Pharmaceuticals Holdings Inc is -40.21M.
Is Corbus Pharmaceuticals Holdings Inc (CRBP) currently rated as Buy, Hold, or Sell?
According to analysts, Corbus Pharmaceuticals Holdings Inc (CRBP) has an overall rating of Buy, with a price target of 42.333.
What is the Earnings Per Share (EPS TTM) of Corbus Pharmaceuticals Holdings Inc (CRBP)?
The Earnings Per Share (EPS TTM) of Corbus Pharmaceuticals Holdings Inc (CRBP) is -5.492.
Related Instruments
+0.38%
+0.19%
-0.77%
-0.15%
-0.08%
-1.56%
+4.46%
-0.24%
+1.17%
-1.09%
-1.39%
-1.38%
+0.07%
-0.25%
-1.30%
+0.20%
-0.12%
0.00%
-0.85%
-1.62%Popular Symbols
257.410
-0.800 (-0.31%)
189.850
+2.800 (+1.50%)
95126.010
-104.660 (-0.11%)
225.040
+2.940 (+1.32%)
3289.970
+4.250 (+0.13%)
445.815
+7.245 (+1.65%)
4613.530
+7.940 (+0.17%)
59.361
+0.522 (+0.89%)
1.162
+0.002 (+0.15%)
157.859
-0.781 (-0.49%)
